Stay updated on Long-Term BMN 190 in CLN2 Disease Clinical Trial
Sign up to get notified when there's something new on the Long-Term BMN 190 in CLN2 Disease Clinical Trial page.

Latest updates to the Long-Term BMN 190 in CLN2 Disease Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page now presents the record for a completed BioMarin extension study evaluating long-term cerliponase alfa (BMN 190) treatment in children with CLN2 disease, including its study design, eligibility criteria, locations, and outcome measures.SummaryDifference50%

- Check16 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedA banner announces NIH's transition to using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI), with links to updates and FAQs. It appears above the inaccessible study record.SummaryDifference1%

- Check30 days agoChange DetectedThe footer now identifies the site revision as v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check37 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1 while the page continues to show a 403 error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study details and related documents with an error screen. This indicates an access/permissions issue preventing the study record from loading.SummaryDifference18%

Stay in the know with updates to Long-Term BMN 190 in CLN2 Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long-Term BMN 190 in CLN2 Disease Clinical Trial page.